EN DE
STOCK COMPARISON

Eagle Pharmaceuticals vs Merck & Company: Fair Value & Quality

Both stocks run through our valuation models. Here is how Eagle Pharmaceuticals (EGRX) and Merck & Company (MRK) compare, as of Aug 31, 2026.

As of Aug 31, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Eagle Pharmaceuticals trades at $0.93 versus a fair value of $0.21 (-77%), while Merck & Company trades at $148 versus $125 (-16%).
Eagle Pharmaceuticals
EGRX · USD · Health Care
-77%
upside to fair value
overvalued
Price$0.93
Fair Value$0.21
Quality69/100
Merck & Company
MRK · USD · Health Care
-16%
upside to fair value
overvalued
Price$148
Fair Value$125
Quality70/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Eagle PharmaceuticalsMerck & Company
Valuation
1.6×P/E (TTM)42.9×
—P/S (TTM)4.64×
—P/B5.80×
—EV/EBITDA11.4×
0.91×PEG6.10×
—Dividend yield2.2%
—Dividend per share$3.28
Profitability
5%Net margin14%
16%Operating margin39%
5%Return on equity19%
7%Return on assets13%
Growth
-13%Revenue growth (YoY)5%
17.4%Avg. growth/yr (3Y)3.1%
6.0%Avg. growth/yr (5Y)9.4%
Balance & size
0.24×Debt / equity0.89×
$3MMarket cap$305B
mixedGrowth qualityhealthy

Merck & Company leads: 4 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Eagle Pharmaceuticalsof which business quality 69 · market factors 46 Merck & Companyof which business quality 68 · market factors 87
ProfitabilityMargins and returns on capital today
65
74
Quality GrowthAre margins and returns improving?
80
36
CashflowEarnings quality: real cash, not paper profit
54
65
Fin. StrengthBalance sheet, leverage, solvency risk
74
68
InvestmentDisciplined investing over empire-building
57
71
Low VolatilityCalm price path (market factor)
44
83
MomentumPrice trend over the last 3–12 months (market factor)
67
82
52W MomentumDistance to the 52-week high (market factor)
12
100
Net IssuanceBuybacks instead of dilution
90
91

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyEagle PharmaceuticalsPrice $0.93Merck & CompanyPrice $148
DCF Models-66%below the price$0.31-21%below the price$117
Earnings-Based-73%below the price$0.25-58%below the price$62.77
Dividend Discount-99%below the price$0.01-59%below the price$60.35
Multiples-74%below the price$0.24-18%below the price$122
Asset-Based-95%below the price$0.04-90%below the price$14.27
Growth DCF-74%below the price$0.24-50%below the price$74.00
Economic Profit-87%below the price$0.12-43%below the price$83.85
Growth Earnings-65%below the price$0.33-7%close to the price$138
Minimum-99%below the price$0.01-90%below the price$14.27
Maximum-65%below the price$0.33-7%close to the price$138
Median-74%below the price$0.24-47%below the price$78.93
Geometric mean-87%below the price$0.12-52%below the price$71.25

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Eagle Pharmaceuticals: 26 of 26 models see the stock below the current price.

Merck & Company: 23 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Eagle Pharmaceuticals
Bear $0.16Fair Value $0.21Bull $0.33
$0.93 = current price (white tick)
Merck & Company
Bear $70.92Fair Value $125Bull $188
$148 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Eagle Pharmaceuticals · Health Care

Quality score69 · Top 25%
Fair value upside-77% · bottom 25%

Merck & Company · Health Care

Quality score70 · Top 25%
Fair value upside-16% · above median

Bottom line

As of Aug 31, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Eagle Pharmaceuticals trades at $0.93 versus a fair value of $0.21 (-77%), while Merck & Company trades at $148 versus $125 (-16%).

Merck & Company has the higher quality score (70/100).

See the full analysis →
Eagle Pharmaceuticals · Merck & Company

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Eagle Pharmaceuticals

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Merck & Company

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.